MIM
FENC icon

MetLife Investment Management’s Fennec Pharmaceuticals FENC Stock Holding History

MetLife Investment Management’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$182K Buy
16,894
+3,385
+25% +$27.6K ﹤0.01% 2472
2026
Q1 		$83.1K Buy
13,509
+490
+4% +$3.78K ﹤0.01% 2610
2025
Q4 		$100K Buy
13,019
+3,426
+36% +$28.1K ﹤0.01% 2598
2025
Q3 		$89.8K Sell
9,593
-5,615
-37% -$48.6K ﹤0.01% 2697
2025
Q2 		$126K Buy
15,208
+3,157
+26% +$21.6K ﹤0.01% 2424
2025
Q1 		$73.4K Sell
12,051
-3,625
-23% -$23.3K ﹤0.01% 2632
2024
Q4 		$99.1K Buy
+15,676
New +$80.3K ﹤0.01% 2627
2024
Q3 		– Sell
-4,526
Closed -$27.7K – 2864
2024
Q2 		$27.7K Sell
4,526
-5,153
-53% -$42.8K ﹤0.01% 2854
2024
Q1 		$108K Hold
9,679
– – ﹤0.01% 2499
2023
Q4 		$109K Hold
9,679
– – ﹤0.01% 2572
2023
Q3 		$72.7K Hold
9,679
– – ﹤0.01% 2746
2023
Q2 		$85.5K Buy
+9,679
New +$80.5K ﹤0.01% 2778
2020
Q3 		– Sell
-11,329
Closed -$94.6K – 2313
2020
Q2 		$94.6K Buy
+11,329
New +$84.3K ﹤0.01% 2272

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCA
Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

MetLife Investment Management's FENC Position: Q2 2026 in Review

MetLife Investment Management increased its Fennec Pharmaceuticals (FENC) stake by 25% in Q2 2026, buying an estimated $27.6K and bringing the position to 16,894 shares worth $182K. The position accounts for ﹤0.01% of the portfolio, ranked #2472.

MetLife Investment Management first reported a position in FENC in Q2 2020 and has held it in 13 quarters since. 104 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

  • MetLife Investment Management held 16,894 shares of Fennec Pharmaceuticals worth $182K as of Q2 2026.
  • MetLife Investment Management bought 3,385 Fennec Pharmaceuticals shares in Q2 2026, an estimated $27.6K.
  • Fennec Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2472 holding.
  • MetLife Investment Management first reported a position in Fennec Pharmaceuticals in Q2 2020 and has held it in 13 quarters since.
  • 104 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.